| |
Explore how oncology developers are adapting to a highly competitive and uncertain oncology therapeutic landscape. .png)
|
|
Today’s Big NewsOct 30, 2024 |
|
Wednesday, November 13 , 2024 | 10am ET / 7am PT Join industry experts to gain insights pertinent to efficient and effective drug development. Understand and execute a risk-based critical thinking approach related to injectable drug packaging and delivery. Register now. 
|
|
| By Nick Paul Taylor Eli Lilly has dropped the lead candidate from its $2.4 billion takeover of Dice Therapeutics, shifting the focus of its oral IL-17 psoriasis program to a follow-up molecule. Lilly kicked DC-806 to the curb as part of a third-quarter cull that also affected the PD-1 autoimmune prospect peresolimab. |
|
|
|
By Zoey Becker After several quarters of creeping up on Humira, Skyrizi is now on top for the Illinois pharma giant. This year, AbbVie's Humira successors are expected to bring in revenues of $17 billion. |
By Fraiser Kansteiner All told, third-quarter U.S. Leqembi sales grew 33% over the prior quarter to $39 million, falling short of consensus estimates. But behind the scenes, there was a 40% uptick in the number of new prescribers writing prescriptions for Leqembi in the third quarter versus Q2, Alicia Alaimo, Biogen’s president and head of North America, said Wednesday. |
By Conor Hale Boston Scientific’s long-awaited Acurate neo2 transcatheter aortic heart valve missed its mark in a study aimed at bringing it to the U.S.—but the company believes it has a fix. |
|
Tuesday, November 12, 2024 | 2pm ET / 11am PT Major breakthroughs have been made recently in the research and development of Alzheimer’s disease. With a stronger understanding of disease pathology, new therapeutic pathways and the launch of the first disease-modifying treatments, join us to learn more about what the future holds in Alzheimer’s disease therapeutic development. Register now. 
|
|
By Nick Paul Taylor GSK has stopped development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a preclinical 30-plus valent shot. A spokesperson for GSK said “increased competition” drove the decision. |
By Eric Sagonowsky Following a report of an ex-AstraZeneca executive being detained in China, the company acknowledged that its current president in the country, Leon Wang, "is cooperating with an ongoing investigation." |
By Conor Hale The Impella ECP is a redesign of the 12-year-old Impella CP, with a structure that lets it to compress to a smaller diameter as it enters the body and navigates the blood vessels. |
By Gabrielle Masson Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the mid-stage study has been tied to one death. |
By Nick Paul Taylor Almirall has put patients’ friends and family at the heart of its activities for the 2024 World Psoriasis Day, launching the “Me & My Inner Circle” campaign to celebrate communities that help people living with the skin condition. |
By Eric Sagonowsky In the wake of a recent round of layoffs, the company this week revealed that it’s discontinuing a commercial medicine and giving up hopes for a pair of pipeline prospects. |
By Gabrielle Masson,Darren Incorvaia,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Medtech's Conor Hale dives into EY's 18th annual Pulse of the MedTech Industry report and chats with EY's John Babbitt about the team's findings and the pace of M&A, venture capital funding and recent IPOs. |
|
|---|
|
|
|
Thursday, November 14, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now. 
|
|
Whitepaper Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
Whitepaper Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
